Skip to content
Vista Pharmaceuticals logo

Vista Pharmaceuticals

524711 BSE
Price unavailable

Vista Pharmaceuticals (VISTAPH) share price was ₹6.14 at the 28 Oct 2026 close; market capitalisation ₹37.79 Cr; sector Healthcare. The share price fell 38.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was under ₹0.01 Cr, against ₹1.52 Cr a year earlier and net profit was −₹0.99 Cr, against −₹1.29 Cr a year earlier (compared with Jun 2025). Promoters held 21.19% of Vista Pharmaceuticals in Jun 2026, unchanged from Mar 2026. Its Tapetide Score is 29/100 (Poor) as of 28 Oct 2026.

Close 28 Oct 2026 ₹6.14 −3.71 −37.66% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹37.79 Cr
EBITDA
−₹14.62 Cr
Return on Equity
-10.23%
Debt to Equity
0.28
Book Value
₹5.92
EPS (TTM)
−₹1.91
52W High
₹10.29
52W Low
₹5.32

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,768.0035.074,24,202 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,657.5087.652,56,376 Cr15.300.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.5072.361,75,331 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.70108.091,18,204 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.6026.291,17,865 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,339.0034.681,11,764 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.5032.711,10,313 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Vista Pharmaceuticals (this company)
——38 Cr1.040.00%-10.23%-9.03%4 Cr-12 Cr
Median 8 companies₹1,768.0035.071,18,035 Cr4.720.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

29 Poor
Overall score

Data confidence 91/100

Category scores

Quality Poor 6
Returns, margins, earnings quality 22% weight
Valuation Weak 43
Cheap vs sector & own history 24% weight
Growth Poor 2
Sales & profit trajectory 9% weight
Financial Health Poor 23
Solvency, leverage, coverage 9% weight
Momentum Poor 28
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Stock is trading at 0.98 times its book value
  • Debtor days have improved from 347 to 21.6 days.

Weaknesses

4
  • Company has low interest coverage ratio.
  • Promoter holding is low: 21.2%
  • Company has a low return on equity of -17.1% over last 3 years.
  • Promoter holding has decreased over last 3 years: -8.32%

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

Bearish

Bearish
7
Neutral
6
Bullish
6

Moving Averages

Neutral

Bearish
5
Neutral
0
Bullish
5

Growth Rate

Revenue Growth
-48.57% lower than 3Y

change over 1 year

Net Income Growth
251% lower than 3Y

change over 1 year

Cash Flow Change
-42.16%

change over 1 year

EBITDA Margin Change
649%

change over 1 year

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1.98
3.47
1.7
3.13
1.8
2.49
2.56
3.23
1.52
1.46
2.42
0
0
Expenses
2.9
4.64
3.44
2.87
2.58
3.32
4.08
4.14
2.63
4.89
5.42
7.06
0.84
Operating Profit
-0.92
-1.17
-1.74
0.26
-0.78
-0.83
-1.52
-0.91
-1.11
-3.43
-3
-7.06
-0.84
OPM %
-46.46%
-33.72%
-102.35%
8.31%
-43.33%
-33.33%
-59.38%
-28.17%
-73.03%
-234.93%
-123.97%
—
—
Other Income
0.13
0.08
0.02
0.1
0.07
0.01
0.12
0.24
0
0.19
0.09
0.03
0.04
Interest
0.33
0.32
0.3
0.28
0.28
0.25
0.22
0.21
0.19
0.18
0.18
0.55
0.34
Depreciation
0.17
0.18
0.18
0.18
0.18
0.18
0.19
0.18
0.18
0.2
0.19
0.19
0.19
PBT
-1.29
-1.59
-2.2
-0.1
-1.17
-1.25
-1.81
-1.06
-1.48
-3.62
-3.28
-7.77
-1.33
Tax %
-25.58%
27.04%
-25.91%
-190%
-26.5%
-22.4%
-26.52%
40.57%
-12.84%
-28.45%
-29.27%
-24.58%
-25.56%
Net Profit
-0.95
-2.02
-1.63
0.09
-0.86
-0.97
-1.32
-1.5
-1.29
-2.59
-2.32
-5.86
-0.99
EPS (₹)
-0.26
-0.55
-0.44
0.02
-0.23
-0.26
-0.36
-0.41
-0.21
-0.42
-0.38
-0.95
-0.16
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
14
15
24
29
31
23
1
0
1
10
10
5
4
Expenses
11
13
21
24
30
28
3
2
5
13
14
20
18
Operating Profit
3
3
3
5
1
-5
-2
-1
-4
-3
-4
-15
-14
OPM %
20%
17%
13%
18%
4%
-21%
-136%
-326%
-432%
-33%
-41%
-271%
-369%
Other Income
0
0
0
0
3
4
0
0
0
0
0
0
0
Interest
0
1
1
2
2
2
2
1
1
1
1
1
1
Depreciation
1
1
1
1
1
1
1
1
1
1
1
1
1
PBT
1
1
1
3
1
-4
-4
-3
-6
-5
-5
-16
-16
Tax %
-9%
8%
-2%
23%
18%
-7%
-47%
-66%
-4%
-13%
-12%
-25%
—
Net Profit
1
1
1
2
1
-4
-2
-1
-6
-5
-5
-12
-12
EPS (₹)
0.11
0.06
0.47
0.75
0.31
-1.21
-0.55
-0.24
-1.54
-1.23
-1.26
-1.96
-1.91
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
6
6
6
7
7
8
9
12
12
Reserves
5
6
11
26
30
24
25
28
29
31
33
24
Borrowings
4
8
11
11
11
15
11
13
10
8
7
10
Other Liabilities
8
7
14
10
6
6
9
8
9
10
7
9
Total Liabilities
23
26
42
53
53
51
53
56
56
58
60
55
Fixed Assets
11
10
13
18
21
21
20
19
20
19
19
18
CWIP
0
0
2
7
9
9
9
9
9
10
10
11
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
12
16
26
28
24
22
24
27
27
29
31
26
Total Assets
23
26
42
53
53
51
53
56
56
58
60
55
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-4
-2
3
-5
3
1
-7
-1
-2
-5
-7
-4
Investing
0
0
-4
-11
-6
-2
0
0
-1
-1
0
-1
Financing
4
3
6
11
1
0
7
1
3
6
8
5
Net Cash Flow
0
0
5
-4
-1
-1
0
0
0
0
1
-1
Free Cash Flow
-4
-3
-1
-15
-2
-1
-7
-1
-3
-6
-7
-5
CFO/OP
-131
-89
84
-86
299
-17
390
78
64
149
163
30
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
300
231
136
137
98
165
624
—
4,106
515
505
22
Inventory Days
10
97
185
250
162
148
4,840
—
991
279
359
770
Days Payable
359
236
293
209
76
79
2,555
—
1,007
304
244
443
Cash Conversion Cycle
-50
92
27
178
184
234
2,909
—
4,089
490
620
349
Working Capital Days
-8
206
12
137
137
81
1,681
—
3,460
318
440
-95
ROCE %
14%
10%
9%
12%
6%
-5%
-5%
-4%
-10%
-8%
-9%
-30%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vista Pharmaceuticals insights

61 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs0.02%Others45.17%Promot.21.19%Public33.63%As ofJun 2026

Documents

Frequently Asked Questions about Vista Pharmaceuticals

What does Vista Pharmaceuticals Ltd do?
Incorporated in 1992, Vista Pharmaceuticals Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]
Where is Vista Pharmaceuticals Ltd (VISTAPH) listed?
Vista Pharmaceuticals Ltd trades under code 524711 on the BSE.
Which sector does Vista Pharmaceuticals Ltd belong to?
Vista Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd has a market capitalisation of ₹37.79 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Vista Pharmaceuticals Ltd?
Over the last 52 weeks Vista Pharmaceuticals Ltd has traded between ₹5.32 and ₹10.29 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Vista Pharmaceuticals Ltd?
Vista Pharmaceuticals Ltd reported a return on equity of -10.23%. Its debt-to-equity ratio is 0.28.

Company Information

Incorporated in 1992, Vista Pharmaceuticals Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]

Website vistapharmaceuticals.com
Face Value ₹ 2
Shares Outstanding 6,15,51,433

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524711.md for Vista Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month